Table 1 Baseline clinical characteristics and angiographic and procedural characteristics
Variables | Atorvastatin (n = 1349) | Rosuvastatin (n = 872) | P-value |
|---|---|---|---|
Men | 1105 (81.9%) | 720 (82.6%) | 0.693 |
Age (years) | 61.0 ± 12.5 | 61.0 ± 12.6 | 0.918 |
LV ejection fraction (%) | 54.1 ± 9.9 | 54.0 ± 9.6 | 0.906 |
Body mass index (kg/m2) | 24.5 ± 3.2 | 24.4 ± 3.4 | 0.442 |
Myocardial infarction | |||
ST-segment elevation | 719 (53.3%) | 478 (54.8%) | 0.483 |
Non-ST-segment elevation | 630 (46.7%) | 394 (45.2%) | |
Hypertension | 549 (40.7%) | 329 (37.7%) | 0.162 |
Cerebrovascular accidents | 42 (3.1%) | 29 (3.3%) | 0.781 |
Total cholesterol (mg/dl) | 195.5 ± 42.0 | 196.6 ± 45.6 | 0.563 |
Triglyceride (mg/dl) | 146.5 ± 120.3 | 145.4 ± 139.1 | 0.852 |
HDL-cholesterol (mg/dl) | 44.1 ± 11.1 | 44.0 ± 11.1 | 0.790 |
LDL-cholesterol (mg/dl) | 126.5 ± 36.3 | 130.6 ± 40.3 | 0.020 |
CK-MB (mg/dl) | 125.2 ± 159.2 | 139.9 ± 145.1 | 0.029 |
Glucose (mg/dl) | 136.7 ± 37.4 | 138.8 ± 37.9 | 0.216 |
Creatinine (mg/dl) | 0.97 ± 0.94 | 0.94 ± 0.42 | 0.340 |
Discharge medications | |||
Aspirin | 1343 (99.6%) | 865 (99.2%) | 0.280 |
Clopidogrel | 855 (63.4%) | 473 (54.2%) | < 0.001 |
Prasugrel | 188 (13.9%) | 68 (7.8%) | < 0.001 |
Ticagrelor | 302 (22.4%) | 325 (37.3%) | < 0.001 |
Cilostazol | 57 (4.2%) | 29 (3.3%) | 0.283 |
Calcium channel blockers | 63 (4.7%) | 45 (5.2%) | 0.600 |
β blockers | 1181 (87.5%) | 714 (81.9%) | < 0.001 |
ACEi | 687 (50.9%) | 321 (36.8%) | < 0.001 |
ARB | 426 (31.6%) | 336 (38.5%) | 0.001 |
Procedural characteristics | |||
Total stent length (mm) | 27.6 ± 12.2 | 39.8 ± 13.4 | < 0.001 |
Total stent number | 1.17 ± 0.41 | 1.20 ± 0.45 | 0.077 |
Stent diameter (mm) | 3.20 ± 0.44 | 3.14 ± 0.44 | 0.062 |